References
1. Brown L.M., Corrado M.M., van der Ende R.M., Derks T.G., Chen M.A., Siegel S., et al. Evaluation of glycogen storage disease as a cause of ketotic hypoglycemia in children. J Inherit Metab Dis. 2015; 38 (3): 489–93. DOI: http://doi.org/10.1007/s10545-014-9744-1
2. Sim S.W., Weinstein D.A., Lee Y.M., Jun H.S. Glycogen storage disease type Ib: role of glucose-6-phosphate transporter in cell metabolism and function. FEBS Lett. 2020; 594 (1): 3–18. DOI: http://doi.org/10.1002/1873-3468.13666
3. Santos B.L., de Souza C.F., Schuler-Faccini L., Refosco L., Epifanio M., Nalin T., et al. Glycogen storage disease type I: clinical and laboratory profile. J Pediatr (Rio J). 2014; 90 (6): 572–9. DOI: http://doi.org/10.1016/j.jped.2014.02.005
4. Zhurkova N.V., Strokova T.V., Zaynudinov Z.M. Inherited metabolic liver diseases. In: B.S. Kaganov (ed.). Pediatric Hepatology. Moscow: Dinastiya, 2009: 320–3. (in Russian)
5. Kaiser N., Gautschi M., Bosanska L., et al. Glycemic control and complications in glycogen storage disease type I: Results from the Swiss registry. Mol Genet Metab. 2019; 126 (4): 355–61. DOI: http://doi.org/10.1016/j.ymgme.2019.02.008
6. Kanungo Sh., Wells K., Tribett T., El-Gharbawy A. Glycogen metabolism and glycogen storage disorders. Ann Transl Med. 2018; 6 (24): 474. DOI: http://doi.org/10.21037/atm.2018.10.59
7. Izmaylova T.D., Surkov A.N. Mitochondrial dysfunction in children with hepatic forms of glycogen storage disease. Vestnik Rossiyskoy akademii meditsinskikh nauk [Bulletin of the RussianAcademy of Medical Sciences]. 2014; 69 (7–8): 78–84. DOI: http://doi.org/10.15690/vramn.v69i7-8.1112 (in Russian)
8. Farah B.L., Sinha R.A., Wu Y., Singh B.K., Lim A., Hirayama M., et al. Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa). Sci Rep. 2017; 7: 44408. DOI: http://doi.org/10.1038/srep44408
9. Strokova T.V., Machulan I.V., Kutyreva E.N., Vorozhko I.V., Kaganov B.S., Dvoryakovskaya G.M. Glycogen-storage disease type 1: clinical and laboratory manifestations in infants and children. Doctor.ru. 2013; (9): 76–81. eLIBRARY ID: 20957711. (in Russian)
10. Prokhorova I.V., Strokova T.V., Bagaeva M.E., Surkov A.G., Pavlovskaya E.V., Taran N.N., et al. Specificities of nutritional status in patients with liver forms of glycogen storage disease. Voprosy detskoy dietologii [Problems of Pediatric Nutrition]. 2018: 16 (6): 5–15. DOI: http://doi.org/10.20953/1727-5784-2018-6-5-15 (in Russian)
11. Prokhorova I.V., Strokova T.V., Kodentsova V.M., Surkov A.G., Bagaeva M.E., Pavlovskaya E.V., et al. Vitamin status in children with hepatic forms of glycogen storage disease. RMJ 2019; 27 (5): 13–19. eLIBRARY ID: 38712202. (in Russian)
12. Strokova T.V., Prokhorova I.V., Surkov A.G., Bagaeva M.E., Pavlovskaya E.V., Taran N.N., et al. Continuous glucose monitoring in children with glycogenosis. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2017; 45 (1): 23–32. DOI: http://doi.org/10.18786/2072-0505-2017-45-1-23-32 (in Russian)
13. Wolfsdorf J.I., Weinstein D.A. Glycogen storage diseases. Rev Endocr Metab Disord. 2003; 4: 95–102. DOI: http://doi.org/10.1023/a:1021831621210
14. Brambilla A., Mannarino S., Pretese R., Gasperini S., Galimberti C., Parini R. Improvement of Cardiomyopathy after high-fat diet in two siblings with glycogen storage disease type III. JIMD Rep. 2014; 17: 91–5. DOI: http://doi.org/10.1007/8904_2014_343
15. Valayannopoulos V., Bajolle F., Arnoux J., et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III with D, L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res. 2011; 70: 638–41. DOI: http://doi.org/10.1203/PDR.0b013e318232154f
16. Rossi A., Hoogeveen I.J., Bastek V.B., et al. Dietary lipids in glycogen storage disease type III: A systematic literature study, case studies, and future recommendations. J Inherit Metab Dis. 2020; 43 (4): 770–7. DOI: http://doi.org/10.1002/jimd.12224.doi:10.1002/jimd.12224
17. El-Gharbawy A.H., Arnold G.L., Perrott-Taylor N., Hughley T., Long K., Vockley J., et al. Optimizing metabolic control of glycogen storage disease type 3 (Gsd3): potential role for medium chain triglycerides (Mct). Mol Genet Metab. 2014; 111: 284–5.
18. Francini-Pesenti F., Tresso S., Vitturi N. Modified Atkins ketogenic diet improves heart and skeletal muscle function in glycogen storage disease type III. Acta Myol. 2019; 38 (1): 17–20. Published 2019 Mar 1. PMID: 31309177 PMCID: PMC6598403
19. Derks T.G., van Rijn M. Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions. J Inherit Metab Dis. 2015; 38 (3): 537–43. DOI: http://doi.org/10.1007/s10545-015-9811-2.
20. Weinstein D.A., Wolfsdorf J.I. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr. 2002; 161: S35–9. DOI: http://doi.org/10.1007/s00431-002-1000-2
21. Ben Chehida A., Ben Messaoud S., Ben Abdelaziz R., et al. A lower energetic, protein and uncooked cornstarch intake is associated with a more severe outcome in glycogen storage disease type III: an observational study of 50 patients. J Pediatr Endocrinol Metab. 2018; 31 (9): 979–86. DOI: http://doi.org/10.1515/jpem-2018-0151
22. Kishnani P.S., Austin S.L., Abdenur J.E., Arn P., Bali D.S., Boney A., et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014; 16 (11): e1. DOI: http://doi.org/10.1038/gim.2014.128
23. James S.P., Rellos P., Ali M. Neonatal screening for hereditary fructose intolerance: frequency of the most common mutant aldolase B allele (A149P) in British population. J Med Genet. 1996; 33: 837–41. DOI: http://doi.org/10.1136/jmg.33.10.837
24. Clinical Recommendations: Inherited tyrosinemia 1 type in children. In: A.A. Baranov AA. Soyuz Pediatrov Russii, 2016: 18 p. (in Russian)
25. Namazova-Baranova L.S., Polyakova S.I., Borovik T.E., Bushuyeva T.V., Varichkina M.A., Gevorkyan A.K. A 7-year experience of therapy with nitisinone of hereditary type 1 tyrosinemia in Russia. Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. 2015 (3): 24–31. eLIBRARY ID: 23239350. (in Russian)
26. de Laet C., Dionisi-Vici C., Leonard J.V., McKiernan P., Mitchell G., Monti L., et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis. 2013; 8: 8. doi: DOI: http://doi.org/10.1186/1750-1172-8-8
27. Obvious medical biochemistry. In: E.S. Severin (ed.). 3rd ed. Moscow: GEOTAR-Media, 2018: 164 p. (in Russian)
28. Russian recommendation on diagnosis and treatment of familial hypercholesterolemia. Moscow, 2017. (in Russian)
29. Bliznyuk S.A., Chubykina U.V., Ezhov M.V. Family hypercholesterolemia in children and adolescents: features of diagnosis and treatment. Pediatriya. Prilozhenie k zhurnalu Consilium Medicum [Pediatrics – Suppl. Consilium Medicum], 2017; (4): 71–3. eLIBRARY ID: 32303535. (in Russian)